Delfin Santos, MD
Rheumatology · Rochester, MINPI 1063420628
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,634 of the $242,220 with a category attached, or 74.6%. 30 manufacturers reported payments, led by Bristol Myers Squibb at 49.2% of the total. Reporting peaked in 2019 at $124,580 and has fallen 99.9% since, to $185 in 2025. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 928 payments — averaging $261.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$119K
- Amgen$77K
- AbbVie$30K
- Pfizer$8K
- Johnson & Johnson$3K
- UCB, Inc.$2K
- plus $3K from 24 others
What the payments were for
- Consulting fees$12,4285%
- Speaking & faculty fees$180,63475%
- Grants$2400%
- Travel & lodging$35,01614%
- Food & beverage$13,6796%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 111 | $119,222 |
| Amgen(2 entities) | 211 | $76,738 |
| AbbVie | 112 | $29,853 |
| Pfizer | 105 | $7,927 |
| Johnson & Johnson | 129 | $2,898 |
| UCB, Inc. | 57 | $2,394 |
| E.r. Squibb & Sons, L.L.C. | 90 | $1,033 |
| Novartis | 28 | $501 |
| Genentech USA, Inc. | 20 | $257 |
| Lilly USA, LLC | 12 | $223 |
| Sanofi | 2 | $169 |
| AstraZeneca(2 entities) | 10 | $162 |
| Boehringer Ingelheim | 5 | $136 |
| GSK | 7 | $105 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| Pacira Therapeutics, Inc. | 2 | $102 |
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Sandoz | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Sobi, Inc | 2 | $39 |
| Hikma Pharmaceuticals USA | 3 | $34 |
| Organon | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Sebela Pharmaceuticals Inc. | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$242,220 in reported general payments places this provider in the 95th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 11 | $74,910 |
| Hydroxychloroquine Sulfate | 23 | $1,723 |
| MethotrexateMethotrexate Sodium | 20 | $874 |
| Prednisone | 30 | $583 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rochester
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
- Barakat ThabetGrand Rapids$128K
- Monika MohanOkemos$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.